0000000000810003
AUTHOR
B. Sanchez
The NHXM observatory
Exploration of the X-ray sky has established X-ray astronomy as a fundamental astrophysical discipline. While our knowledge of the sky below 10 keV has increased dramatically (∼8 orders of magnitude) by use of grazing incidence optics, we still await a similar improvement above 10 keV, where to date only collimated instruments have been used. Also ripe for exploration is the field of X-ray polarimetry, an unused fundamental tool to understand the physics and morphology of X-ray sources. Here we present a novel mission, the New Hard X-ray Mission (NHXM) that brings together for the first time simultaneous high-sensitivity, hard-X-ray imaging, broadband spectroscopy and polarimetry. NHXM will…
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…